Philippe Leduc-Thompson

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)

Published: July 14, 2026

Real-world treatment patterns and clinical burden of patients with hereditary angioedema treated with long-term prophylaxis.

Real-world treatment patterns and clinical burden of patients with hereditary angioedema treated with long-term prophylaxis.

Journal: Orphanet journal of rare diseases

Published: December 03, 2025

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma.

Journal: Journal of managed care & specialty pharmacy

Published: September 15, 2025

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Journal: Cancer medicine

Published: August 07, 2024

Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy.

Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy.

Journal: Pharmacology research & perspectives

Published: June 07, 2024

Dr Singer et al reply.

Dr Singer et al reply.

Journal: The Journal of rheumatology

Published: March 01, 2024

Development and validation of a claims-based algorithm to identify moderate exacerbations in patients with asthma treated in the US.

Development and validation of a claims-based algorithm to identify moderate exacerbations in patients with asthma treated in the US.

Journal: Respiratory medicine

Published: November 10, 2023

Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study.

Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study.

Journal: Respiratory medicine

Published: November 10, 2023

Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.

Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.

Journal: BMJ open respiratory research

Published: October 13, 2023

Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.

Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States.

Journal: Psoriasis (Auckland, N.Z.)

Published: August 11, 2023

Burden of Herpes Zoster Among Patients with Psoriasis in the United States.

Burden of Herpes Zoster Among Patients with Psoriasis in the United States.

Journal: Dermatology and therapy

Published: June 05, 2023

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 31, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026